What is RNAimmune?
RNAimmune operates at the intersection of biotechnology and artificial intelligence, specializing in the discovery and development of mRNA-based therapeutics. Founded in 2020, the firm utilizes its proprietary Polypeptide Lipid Nanoparticle (PLNP) technology, licensed exclusively from Sirnaomics, to facilitate efficient mRNA delivery. Complementing this delivery mechanism is the company's ALEPVA artificial intelligence algorithm, which optimizes antigen prediction and vaccine design. This dual-platform approach allows RNAimmune to function as a comprehensive drug discovery engine, effectively instructing the human body to produce therapeutic proteins. By targeting high-growth sectors such as cancer immunotherapy and viral disease prevention, the company has established itself as a critical player in the next generation of precision medicine.
How much funding has RNAimmune raised?
RNAimmune has raised a total of $39.4M across 3 funding rounds:
Angel/Seed
$2.4M
Angel/Seed
$10M
Series A
$27M
Angel/Seed (2020): $2.4M with participation from Terra Magnum Capital Partners
Angel/Seed (2021): $10M led by Smooth River and Hongrun
Series A (2022): $27M supported by Sirnaomics and Smooth River
Key Investors in RNAimmune
Sirnaomics
A biopharmaceutical firm with a global footprint, specializing in the discovery and development of RNAi therapeutics and mRNA vaccines through proprietary delivery platforms.
Smooth River
A diversified investment entity that has provided early and growth-stage backing to support the company's technological infrastructure and operational scaling.
Hongrun
A leader in precision instrumentation and intelligent manufacturing, bringing industrial expertise and a focus on high-performance technology integration to the investment syndicate.
What's next for RNAimmune?
Looking ahead, RNAimmune is poised to leverage its recent capital influx to transition from platform development to clinical-stage execution. The strategic focus will likely center on scaling the ALEPVA algorithm's capabilities and expanding the therapeutic pipeline into human trials. As the biopharmaceutical sector increasingly pivots toward mRNA-based solutions, RNAimmune's ability to integrate AI-driven design with advanced delivery systems provides a distinct competitive advantage. Future milestones will likely involve deepening partnerships with global research institutions and optimizing manufacturing processes to support large-scale clinical applications, ensuring the company remains at the forefront of mRNA innovation.
See full RNAimmune company page
